Differing Effects of Staurosporine and UCN-01 on RB Protein Phosphorylation and Expression of Lung Cancer Cell Lines

Oncology (Switzerland)

Volumn 53, Issue 6, 1996, Pages 494-504

  Shimizu, Eiji ^a   Zhao, MeiRong ^a   Nakanishi, Hirofumi ^a   Yamamoto, Akiyoshi ^a   Yoshida, Seiji ^a   Takada, Minoru ^b   Ogura, Takeshi ^a   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

Lung cancer; RB protein; Staurosporine; UCN 01

Indexed keywords

HYDROXYL GROUP; RETINOBLASTOMA PROTEIN; STAUROSPORINE; STAUROSPORINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; DEPHOSPHORYLATION; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CANCER; LUNG SMALL CELL CANCER; METAPHASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE;

ALKALOIDS; CELL CYCLE; CELL DIVISION; DNA, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE C; RETINOBLASTOMA PROTEIN; STAUROSPORINE; TUMOR CELLS, CULTURED;

EID: 0029958166     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227626     Document Type: Article

References (45)

1. Lee W-H, Shew J-Y, Ilong FD, Scry TW, Don-oso I.A, Young L-J, Bookstein R, Lee EY-HP: The retinoblastoma susceptibility gene encodes a nuclear phosphoprotcin associated with DNA binding activity, Nature 1987:329:642- 645.
2. Horowitz JM, Park S-H, Bogenmann E, Cheng J-C, Yandcll DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA: Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells, Proc Natl Acad Sci USA 1990;87:2775-2779.
3. Friend SH, Bernards R, Rogclj S, Weinberg RA, Rapaporl JM, Albert DM, Dryja TP: A human DNA segment w'ith properties of the gene that predisposes to retinoblastoma and osteosarcoma, Nature 1986:323:643-646.
4. Harbour JW, Lai S-L, Whang-Peng J, Gazder AF, Minna JD, and Kaye FJ: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC, Science 1988:241: 353-357.
5. Yokota J, Akiyama T, Fung Y-KT, Benedict WF, Namba Y, Hanaoka M, Wada M, Tcrasa-ki T, Shimosato Y, Sugimura T, Terada M: Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung, Oncogene 1988:3:471-475.
6. Horowitz JM, Yandcll DW, Park S-H, Canning S, Whyte P, Buchkovich K, Harlow E, Weinberg RA, Dryja TP: Point mutational inactivation of the retinoblastoma antioncogene, Science 1989:243:937-940.
7. Lee EY-HP, To H, Shew J-Y, Bookstein R, Scully P, Lee W-H: Inactivation of the retinoblastoma susceptibility gene in human breast cancers, Science 1988:241:218-221.
8. Tang A, Varley JM, Chakraborty S, Murphrec AL, Fung Y-KT: Structural rearrangement of the retinoblastoma gene in human breast carcinoma, Science 1988;242:263-266.
9. Ginsberg AM, Raffeld M, Cossman J: Inactivation of the retinoblastoma gene in human lymphoid neoplasms, Blood 1991:77:833-840.
10. Furukawa Y, DeCaprio JA, Belvin M, Griffin JD: Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells, Oncogene 1991:6: 1343-1346.
11. Sasano H, Comerford J, Silverberg SG, Garrett CT: An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma, Cancer 1990;66:2150-2154.
12. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzkc RA, Kim YW, Fedorko J, Oie H, Johnson BE, Mulshine JL, Minna JD, Gazder AF, Kaye FJ: RB protein status and clinical correlation from 172 cell lines representing lung cancer, cxtrapulmonary small cell carcinoma, and mesothelioma, Oncogene 1994:9: 2441-2448.
13. Huang H-JS, Yce J-K, Shew J-Y, Chen P-L, Bookstein R, Friedmann T, Lee EY-HP, Lee W-H: Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells, Science 1988:242:1563-1566.
14. Bucnovich K, Duffy LA, and Harlow E: The retinoblastoma protein is phosphorylatcd during specific phases of the cell cycle, Cell 1989: 58:1097-1105.
15. Chen P-L, Scully P, Shew J-Y, Wang JYJ, Lee WH: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation, Cell 1989:58: 1193-1198.
16. DeCaprio JA, Luldlow JW, Lynch D, Fukuka-wa Y, Griffin J, Piwinica-Worms H, Huang C-M, Livingston DM: The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element, Cell 1989:58: 1085-1095.
17. Lin BT, Greunwald S, Morla AO, Lee WH, Wang JY: Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator of cdc2 kinase, EMBO J 1991:10:857-864.
18. Devoto SH, Mudryj M, Pines J, Hunter T, Nevins JR: A cyclin A-protcin kinase complex possesses sequence-specific DNA binding activity: p33cdk2 is a component of the E2F-cyclin A complex, Cell 1992:68:167-176.
19. I Iu Q, Lees JA, Buchkovich KJ, Harlow E: The retinoblastoma protein physically associates with the human cdc2 kinase, Mol Cell Biol 1992:12:971-980.
20. Akiyama T, Ohuchi T, Sumida S, Matsumoto K, Toyoshima K: Phosphory lation of the retinoblastoma protein by cdk2, Proc Natl Acad Sci USA 1992:89:7900-7904.
21. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implication for cellular regulation, Nature 1988;334:661-665.
22. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M: Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models, Cancer Res 1991:51:4888-4892.
23. 2*-dependent protein kinase, Biochem Biophys Res Com-mun 1986;135:397-402.
24. Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakano H: UCN-01, a selective inhibitor of protein kinase C from Streptomyces, J Antibiot (Tokyo) 1987;40:1782-1784.
25. Takahashi I, Saitoh Y, Yoshida M, Sano H, Nakano H, Morimoto M, Tamaoki T: UCN-01 and UCN-02, new selective inhibitors of protein kinase C, II, Purification, physico-chemical properties, structural determinations, and biological activities, J Antibiot (Tokyo) 1989; 42:571-576.
26. Meyer TT, Regenass U, Fabbro D, Alteri E, Rosel J, Muller M, Caravatti G, Matter A: A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity, Int J Cancer 1989:43: 851-856.
27. Masuda N, Fukuoka M, Takada M, Kudoh S, Kusunoki Y: Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4), Chest 1991;100:429-438.
28. Gazder AF, Oie HK: Cell culture methods for human lung cancer, Cancer Genet Cytogenet 198619:5-10.
29. Carmichael J, Mitchell JB, DcGraff WG, Gam-son J, Gazder AF, Johnson BE, Glatstcin E, Minna JD: Chemosensitivitv testing of human lung cancer cell lines using the MTT assay, Br, J Cancer 1985;57:540-547.
30. Tsai C-M, Gazder AF, Venzon DJ, Steinberg SM, Dcdrick RL, Mulshine JL, Kramer BS: Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum (II), Cancer Res 1989;49:2390-2397.
31. Kaye FJ, Kratzke RA, Grester JL, Horowitz JM: A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding, Proc Natl Acad Sci USA 1990;87:6922-6926.
32. Kase H, Iwahashi K, Matsuda Y: K-252a, a potent inhibitor of protein kinase C from microbial origin, J Antibiot (Tokyo) 1986:39: 1059-1065.
33. Nakano H, Kobayashi E, Takahashi I, Tamaoki T, Kuzuu Y, Iba H: Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60, J Antibiot (Tokyo) 1987:40:706-708.
34. Rucgg UT, Burgess GM: Staurosporine, K-252a, and UCN-01: potent but nonspecific inhibitors for protein kinase, Trends Pharmacol Sci 1989;10:218-220.
35. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausvillc EA, Worland PJ: Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells, Cancer Res 1993:53:2081- 2086.
36. Abe K, Yoshida M, Usui T, Horinouchi S, Bep-pu T: Highly synchronous culture of fibroblasts from G2 block caused by staurosporine, a potent inhibitor of protein kinase, Exp Cell Res 1991;192:122-127.
37. Bruno S, Ardelt B, Skierski JS, Traganos F, Darzynkicwicz Z: Different effects of stauro-sporine, an inhibitor of protein kinases, on the cell cycle and chromatin structure of normal and leukemic lymphocytes, Cancer Res 1992; 51:470-473.
38. Crissman HA, Gadbois DM, Tobcy RA, Bradbury EM: Transformed mammalian cells are deficient in kinasc-mcdiated control of progression through the G1 phase of the cell cycle, Proc Natl Acad Sci USA, 1991;88:7580-7584.
39. Usui T, Yoshida M, Abe K, Osada H, Isono K, Bcppu T: Uncoupled cell cycle without mitosis induced by a protein kinase inhibitor, K-252a, J Cell Biol’ 1991:1 15:1275-1282.
40. Akinaga S, Nomura K, Gomi K, Okabe M: Effec: of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells, Cancer Chemother Pharmacol 1994:33:273- 280.
41. Meek DW, Street AJ: Nuclear protein phosphorylation and growth control, Biochem J 1992;287:1-15.
42. Norbury C, Nurse P: Animal cell cycles and their control, Annu Rev Biochem 1992;61: 441-470.
43. Pines A, Hunter T: Human cyclin A is adenovirus ElA-associatcd protein p60 and behaves differently from cyclin B, Nature 1990:346: 760-763.
44. Xiong Y, Connolly B, Futcher B, Beach D: Human D-type cyclin, Cell 1991;65:691-699.
45. Gadbois DM, Hamaguchi JR, Swank RA, Bradbury EM: Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases, Biochem, Biophys ResCommun 1992;184:80-85.